Clinical trial
Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified…
NCT00356811 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00356811 |
|---|---|
| Title | Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer |
| Official title | An Open-label, Single-arm, Multi-centre, Phase II Study of Oral Lapatinib in Combination With Paclitaxel as First-line Treatment for ErbB2-amplified Metastatic Breast Cancer Patients |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms, Breast |
| Intervention type | Drug |
| Interventions | Lapatinib oral tablets, Paclitaxel infusion |
| Enrollment | 57 |
| Start date | May 1, 2006 |
| Primary completion | Mar 1, 2008 |
| Completion | Dec 1, 2013 |
| First posted | Jul 26, 2006 |
| Last update posted | Jul 21, 2014 |
| Countries | Latvia, Poland, Romania, Russia |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: